CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed
Drug / intervention
TNP-470drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000763
NCT00000763Phase 1Completed
CompareCT.gov

A Phase I Study of TNP-470 in the Treatment of AIDS-Associated Kaposi's Sarcoma

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Aug 31, 2001·Updated Nov 3, 2021

In Brief

A Phase 1 clinical trial evaluating TNP-470 for Sarcoma, Kaposi and HIV Infections. Completed, across 6 sites.

Detailed Summary

To assess toxicity and determine the MTD of intravenous TNP-470 administered weekly in patients with AIDS-related Kaposi's sarcoma. To assess pharmacokinetics and tumor response of the drug. Since evidence shows that neovascularization is important in the development of Kaposi's sarcoma, drugs that inhibit angiogenesis, such as TNP-470, may be of benefit in patients with the disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcoma, Kaposi, HIV Infections
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 31, 2001
Study CompletionFeb 1, 1997
TodayJul 2, 2026
Posted 24.8 years ago

Interventions

TNP-470drug